These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20509268)

  • 1. [Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
    MMW Fortschr Med; 2010 Apr; 152(17):68-9. PubMed ID: 20509268
    [No Abstract]   [Full Text] [Related]  

  • 2. The continuing evolution of HIV therapy.
    Boyle BA
    AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atazanavir-induced nephrolithiasis].
    Valencia ME; Moreno V
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract]   [Full Text] [Related]  

  • 5. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
    Kuritzkes DR
    J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
    [No Abstract]   [Full Text] [Related]  

  • 6. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 7. Rilpivirine: a step forward in tailored HIV treatment.
    Schrijvers R; Desimmie BA; Debyser Z
    Lancet; 2011 Jul; 378(9787):201-3. PubMed ID: 21763920
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
    Bayonne Kombo ES; Gathse A
    Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
    [No Abstract]   [Full Text] [Related]  

  • 9. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 10. Promising new agents on the horizon.
    Feinberg J
    AIDS Clin Care; 2002 Mar; 14(3):22. PubMed ID: 12141239
    [No Abstract]   [Full Text] [Related]  

  • 11. Boosting HIV treatment options: good news, new challenges.
    Cahn P; Sued O
    J Infect Dis; 2013 Jul; 208(1):4-6. PubMed ID: 23532095
    [No Abstract]   [Full Text] [Related]  

  • 12. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 13. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
    Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
    J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical data II. Clinical experience of tenofovir DF in combination with protease inhibitors].
    Pulido F; Fiorante S
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():13-8. PubMed ID: 19195433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs in development.
    Proj Inf Perspect; 1998 Sep; (25):8. PubMed ID: 11365851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
    Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigating new antiretroviral combinations.
    Carr A
    J Infect Dis; 2006 Jun; 193(12):1742; author reply 1742-3. PubMed ID: 16703520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.